A useful map of the psychedelic pipeline starts from a counterintuitive number: there are fewer than ten companies with Phase 2 or later psychedelic programs targeting psychiatric indications, and the FDA’s April 24 voucher selections concentrated the field’s near-term commercial value into three of them. The press coverage tends to make the field sound broader than it is. The actual roster of sponsors capable of producing a marketable psychedelic drug in the next 24 to 36 months is small, and the programs are concentrated in a narrow set of molecules.

This is a reference map of where each surviving developer sits as of June 2026. The programs are listed in approximate order of near-term commercial maturity. Where data is public, it is sourced. Where private companies have not disclosed details, the entry says so.

Compass Pathways (CMPS)

The most advanced psychedelic developer in the public market. Two completed Phase 3 trials of synthetic psilocybin (COMP360) in treatment-resistant depression. COMP005 read out in June 2025; COMP006 read out in February 2026. Both met their primary endpoints with statistically significant separation from placebo. Compass received a Commissioner’s National Priority Voucher on April 24 and a rolling NDA review the same day. The company is targeting NDA submission in Q4 2026. Approval, on the one-to-two-month voucher review window, could plausibly arrive in late 2026 or early 2027, making COMP360 the first classic psychedelic ever approved by the FDA.

The company has stated that its commercial strategy assumes a healthcare-provider-administered model, with dosing sessions conducted in clinical settings. The reimbursement architecture for this model is not yet built; one of the open questions in the field is whether payers will accept the model when the approval arrives, and at what reimbursement levels.

Compass remains a pure-play psychedelic developer; psilocybin is the only program in active development. The company’s commercial fate depends almost entirely on this single asset’s regulatory and commercial trajectory over the next 18 months.

AtaiBeckley (ATAI)

Formed by the November 2025 strategic combination of atai Life Sciences and Beckley Psytech. The combined company holds a more diversified pipeline than any other public psychedelic developer. Lead asset: BPL-003 (mebufotenin benzoate, intranasal). Phase 2b data in treatment-resistant depression read out in mid-2025, meeting primary and key secondary endpoints. The company received FDA Breakthrough Therapy designation for BPL-003 and was preparing for End-of-Phase 2 meetings as of Q3 2025. BPL-003 was not selected for a Commissioner’s National Priority Voucher in April; the FDA’s selections for TRD-adjacent indications went to Compass and Usona.

Beyond BPL-003, AtaiBeckley has two Phase 2 programs: VLS-01 (DMT buccal film) for TRD and EMP-01 (oral R-MDMA) for social anxiety disorder. The company is also advancing a preclinical drug discovery program in non-hallucinogenic 5-HT2A receptor agonists, supported in part by an NIDA grant for opioid use disorder.

The diversification matters strategically. If COMP360 reaches approval first, AtaiBeckley is positioned as the second wave with a differentiated mechanism (BPL-003’s much shorter time-in-clinic profile is a real commercial advantage if it holds in Phase 3). If COMP360 stumbles, AtaiBeckley has multiple shots on goal.

Cybin (CYBN)

Lead asset CYB003 (deuterated psilocybin analog) for major depressive disorder. Received FDA Breakthrough Therapy designation in March 2024. Phase 3 program (APPROACH-1 and EMBRACE) is ongoing. Cybin was not selected for an April voucher. The company has discussed expanding into other indications, but the near-term commercial story remains CYB003 in MDD.

Cybin’s positioning is structurally similar to Compass: a single-asset psilocybin developer competing in essentially the same indication space, with a differentiated formulation (the deuterated analog) but the same core mechanism. The competitive question is whether the differentiation is meaningful enough to support a second psilocybin entrant if Compass approves first.

GH Research (GHRS)

Lead asset GH001 (inhaled 5-MeO-DMT) for treatment-resistant depression. The molecule is structurally distinct from psilocybin and MDMA, with a much shorter duration of action (typically 20-40 minutes versus four to eight hours for psilocybin). Phase 2 data has been positive on multiple cohorts. GH Research was not selected for an April voucher.

The 5-MeO-DMT mechanism is the wild card in the field. If GH001’s Phase 3 data holds, it offers a commercial profile that the longer-duration psychedelics cannot: dosing sessions that fit inside a normal medical appointment rather than requiring a full-day clinical encounter. This is a structural advantage for healthcare delivery and for payer acceptance, if the efficacy holds at scale.

MindMed / Definium (MNMD)

The company rebranded from MindMed to Definium in late 2025 as part of a strategic repositioning. Lead asset MM120 (LSD-based, in a proprietary formulation) for generalized anxiety disorder. MM120 received FDA Breakthrough Therapy designation in 2024. Phase 3 program ongoing.

The GAD indication is differentiated from the TRD/MDD focus of the other major developers, which gives MindMed/Definium a less crowded competitive space if approval is reached. But it also means the company is testing a mechanism (LSD-based) in an indication (anxiety) without the precedent of an approved psychedelic to draw on for reimbursement and prescribing patterns.

Usona Institute (private nonprofit)

Phase 3 program of synthetic psilocybin (PSIL201) in major depressive disorder. Received FDA Breakthrough Therapy designation in 2019. Received a Commissioner’s National Priority Voucher on April 24, alongside Compass and Transcend.

Usona’s status as a nonprofit creates an unusual commercial structure. The organization does not appear to have a standing commercial team capable of launching an approved drug. If PSIL201 reaches approval on the accelerated timeline the voucher creates, Usona will likely need a commercial partner to handle launch, marketing, and distribution. The question of who that partner will be is one of the more interesting open questions in the field. The candidates include incumbent pharmaceutical companies looking for a psychedelic entry point (Otsuka has already moved on this with Transcend; Johnson & Johnson has esketamine and may want to expand), and specialty psychiatric drug companies looking for differentiation (Axsome, Sage, others).

Transcend Therapeutics / Otsuka Pharmaceutical (OTSKY)

Transcend’s lead asset TSND-201 (methylone) for PTSD. Phase 2 trial (IMPACT-1) published in JAMA Psychiatry in February 2026, met primary endpoint. Received a Commissioner’s National Priority Voucher on April 24. Otsuka Pharmaceutical announced a $1.225 billion acquisition of Transcend the same week, attaching the voucher to Otsuka post-close.

This is structurally the most consequential transaction in the field’s recent history. Otsuka brings commercial infrastructure (the company already markets aripiprazole and operates a global psychiatric specialty sales force), regulatory experience, and capital. Transcend brings the voucher, the Phase 2 data, and a Phase 3-ready program in PTSD that the FDA has signaled it is willing to accelerate. The combination is positioned to be the first psychedelic launch in PTSD, in a field where Lykos’s MDMA program failed and Resilient has not relaunched.

The molecule itself, methylone, is closely related to MDMA but with a different pharmacokinetic profile (shorter duration, less prolonged elevation of body temperature and blood pressure). The differentiation is methodologically interesting; whether it is commercially differentiated will depend on Phase 3 data and the eventual label.

Resilient Pharmaceuticals (private, formerly Lykos Therapeutics, formerly MAPS Public Benefit Corporation)

The most documented program in the field’s history. The August 2024 Complete Response Letter for midomafetamine (MDMA-AT) was made public on September 4, 2025, when the FDA released 89 previously unpublished CRLs. The letter remains public reading and is the most detailed regulatory document on any psychedelic program.

Resilient was not selected for an April voucher. The company has stated its intent to engage with the FDA on resubmission, but has not, by available reporting, launched the additional Phase 3 trial the original CRL requested. The workforce reduction of approximately 75 percent in August 2024 has not been reversed. The leadership turnover (founder Rick Doblin departed the board, CEO Amy Emerson stepped down in September 2024) has not been replaced with executives with comparable industry stature.

The structural question is whether Resilient is a company with a future in MDMA development or a company conducting an orderly wind-down of a program the FDA has not been persuaded to reconsider. The available evidence is consistent with either reading. The next 12 months will likely clarify which is correct.

Academic and pre-Phase-2 programs

The Johns Hopkins, Imperial College London, NYU, and UCSF psychedelic research programs continue to produce trial data, but their programs are academic rather than commercial. None are positioned to file an NDA or launch a commercial product. They function as research infrastructure that informs the field but does not directly produce approvable assets.

Several smaller developers (Awakn Life Sciences, Filament Health, Atai’s various preclinical programs, the DemeRx noribogaine program now cleared to begin U.S. clinical trials) sit at earlier stages. These are real programs but not on a near-term commercial timeline. Their relevance to the next 24 to 36 months is limited to the question of what comes after the current wave of Phase 3 programs reaches their regulatory outcomes.

The structural reading

Looking at the pipeline as a whole, three things stand out.

The first is concentration. Three programs (Compass COMP360, Otsuka/Transcend TSND-201, Usona PSIL201) hold vouchers and have a credible path to approval in the next 18 to 24 months. AtaiBeckley’s BPL-003 is the most credible fourth, on a Phase 3 timeline that places it behind the voucher recipients by approximately 12 months. Cybin’s CYB003 and MindMed/Definium’s MM120 are real Phase 3 programs but in indications and timelines that put them in a second commercial wave.

The second is mechanism convergence. Three of the four most advanced programs are psilocybin or psilocybin-analog: COMP360, PSIL201, CYB003. The methodological and regulatory framework being established for one will substantially determine how the others are evaluated. The first psilocybin approval, if it comes, will be precedent-setting for the others in ways that compress the differentiation between them.

The third is the gap left by Resilient. The PTSD indication was supposed to be MDMA’s indication. The methylone program now occupies that space. If TSND-201 reaches approval in PTSD before MDMA-AT does, the commercial logic for relaunching MDMA-AT in the same indication becomes harder to construct. The window for Resilient to reposition is narrow and closing.

The press coverage of the field tends to treat each new program announcement as additive. The structural reality is closer to subtractive: a narrow field of survivors, with overlapping mechanism bets, competing for the same regulatory framework and the same eventual reimbursement architecture. The next 18 months will determine which of the survivors graduates to commercial product and which of them ends up as a clinical-stage company that ran out of runway.

Behavioral Wire will be tracking these programs continuously. The pipeline tracker on the homepage carries the same data in structured form, with milestones updated as they happen. This piece is the narrative version of what the tracker shows.